Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated medical claim that DALIRESP reduces the risk/rate of COPD exacerbations in severe COPD with chronic bronchitis and a history of exacerbations is directly supported by the label’s Indications and Usage and Clinical Studies, with appropriate acknowledgement of the label’s maintenance/limitation context (not for acute bronchospasm).
Category Scores
Accurate Statements
DALIRESP (roflumilast) is indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Section 1 INDICATIONS AND USAGE: “indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.”
The clinical studies provide evidence supporting DALIRESP use for reduction of COPD exacerbations (e.g., DALIRESP 500 mcg once daily significantly reduces the rate of moderate or severe exacerbations vs placebo).
Section 14.1: “DALIRESP 500 mcg once daily demonstrated a significant reduction in the rate of moderate or severe exacerbations compared to placebo… These two trials provide the evidence to support the use of DALIRESP for the reduction of COPD exacerbations.”
DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.
Section 1 Limitations of Use: “DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.” and Section 5.1: “DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm.”
The dosing includes an initial 250 mcg once daily for 4 weeks and an increase to 500 mcg once daily thereafter, and 250 mcg/day is not the effective (therapeutic) dose.
Section 2 DOSAGE AND ADMINISTRATION: “Starting treatment with a dose of DALIRESP 250 mcg once daily for 4 weeks and increasing to DALIRESP 500 mcg once daily thereafter… However, 250 mcg per day is not the effective (therapeutic) dose.”
Unsupported Statements
Contradictions
Important Omissions
No mention in the evaluated claim of the specific dosing (500 mcg maintenance dose) as part of the actual claim wording; however, the response did discuss dose/titration in notes rather than as the core claim.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim aligns with on-label indications for maintenance reduction of COPD exacerbation risk and does not suggest use for acute bronchospasm relief; no contraindications, boxed warnings, or dosing errors were asserted in the core claim.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
None material detected for the core indication claim.
Suggested Improvement
If the goal is to be maximally label-faithful, specify that the evidence discussed pertains to DALIRESP 500 mcg once daily (maintenance) rather than framing solely as a general “risk/rate reduction.”